Sorcero, a leader in AI-powered analytics for life sciences, has acquired Axiom Health, a real-world data platform for the medical technology industry. This acquisition launches Sorcero MedTech, creating the first unified AI platform for pharmaceutical and medical device organizations. By integrating Axiom Health’s data lake with Sorcero’s Intelligence Platform, the company enables comprehensive insights into patient journeys, product development, and commercialization strategies across healthcare sectors.
Sorcero acquires Axiom Health, launching Sorcero MedTech.
Unified AI platform for pharma and medical device insights.
Enables cross-vertical analysis for better patient outcomes.
Targets $595B MedTech market with enhanced intelligence.
Supports stakeholder micro-targeting and commercialization.
Backed by First Trust Capital Partners for growth.
The acquisition integrates Axiom Health’s medical device data with Sorcero’s AI-driven analytics, creating a unified platform for life sciences. “The integration of pharmaceutical and medical device data unlocks critical insights that have been siloed for too long,” said Dipanwita Das, CEO of Sorcero. This enables life sciences teams to analyze treatment pathways holistically, driving informed decisions in product development and market strategies.
Sorcero MedTech positions the company in the $595 billion medical technology market, as reported by Medical Product Outsourcing. The platform offers cross-vertical analysis, combining pharma, medical device, and stakeholder data for rapid insights. “By combining Axiom Health’s market-leading medtech data with Sorcero’s AI platform, we can now provide a single source of truth delivering unified device and drug insights,” said A. Krishna, Senior Vice President of MedTech at Sorcero.
The enhanced platform supports stakeholder micro-targeting, allowing companies to understand product usage across medical devices and pharmaceuticals. This capability drives personalized engagement with physicians and key opinion leaders (KOLs), addressing unmet patient needs. The platform also provides market intelligence to optimize commercial strategies, strengthening Sorcero’s value proposition for life sciences organizations.
Backed by First Trust Capital Partners, the acquisition fuels Sorcero’s growth in the expanding life sciences AI market. “The integration of medical device commercial intelligence with Sorcero’s established pharmaceutical analytics platform addresses a critical market need,” said Jon Phillips, Managing Director at First Trust Capital Partners. The unified platform is poised to reshape how life sciences companies leverage data to improve patient care and accelerate innovation.
Sorcero’s acquisition of Axiom Health marks a significant step toward delivering AI-driven, unified insights, empowering life sciences and medical device organizations to enhance patient outcomes and drive strategic growth.
Sorcero is a leading provider of AI-powered solutions for the life sciences industry, dedicated to improving patient outcomes through innovative technology. By combining advanced natural language processing with domain-specific expertise, Sorcero develops tools that transform how healthcare and pharmaceutical professionals access and utilize critical information. The company's innovation has been recognized by over a dozen awards, including Google Business Applications Partner of the Year for Healthcare & Life Sciences in 2025, and six foundational medical AI patents.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.